First data presented from phase 2 BEYOND study of Reblozyl (luspatercept-aamt) in adults with non-transfusion dependent beta thalassemia

RCT (n=145) found from weeks 13-24, in absence of transfusions, significantly more patients treated with this first-in-class erythroid maturation agent plus best supportive care achieved primary endpoint, ≥1.0 g/dL mean Hb increase from baseline vs placebo (77.1 vs. 0%; p<0.0001)

Source:

Biospace Inc.